Literature DB >> 19531543

The predictive role of E-cadherin and androgen receptor on in vitro chemosensitivity in triple-negative breast Cancer.

Ja Seung Koo1, Woohee Jung, Joon Jeong.   

Abstract

OBJECTIVE: The purpose of this study was to evaluate the impact of various pathologic and biologic factors in triple-negative breast cancer (TNBC) on chemotherapy response using in vitro ATP-based chemotherapy response assay (ATP-CRA).
METHODS: Forty-seven cases of TNBC were included. Immunohistochemical stains for androgen receptor (AR), p53, CD10, c-kit, CK5/6, vimentin, bcl-2, E-cadherin, Ki-67 and epidermal growth factor receptor were performed. In vitro ATP-CRA was used to analyze chemosensitivity for 5-fluorouracil (5-FU), docetaxel, doxorubicin, epirubicin, vinorelbine, gemcitabine, methotrexate (MTX), oxaliplatin and paclitaxel.
RESULTS: The results showed that all cytotoxic agents demonstrated the trend that E-cadherin-expressing cases had a higher cell death rate than E-cadherin-negative cases. Particularly, vinorelbine showed statistical significance (P = 0.004). Cases with AR expression showed higher cell death rates than those without in 5-FU and MTX (P = 0.012 and 0.014, respectively).
CONCLUSIONS: E-cadherin and AR could be candidate predictive factors for chemotherapy response in TNBC. Further in vivo study is required to clarify their roles.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19531543     DOI: 10.1093/jjco/hyp065

Source DB:  PubMed          Journal:  Jpn J Clin Oncol        ISSN: 0368-2811            Impact factor:   3.019


  10 in total

1.  The expression and clinical significance of the androgen receptor and E-cadherin in triple-negative breast cancer.

Authors:  Dabei Tang; Shanqi Xu; Qingyuan Zhang; Wenhui Zhao
Journal:  Med Oncol       Date:  2011-04-26       Impact factor: 3.064

2.  Androgen Receptor Expression in an Indian Breast Cancer Cohort with Relation to Molecular Subtypes and Response to Neoadjuvant Chemotherapy - a Prospective Clinical Study.

Authors:  Akshay Anand; Kul R Singh; Surender Kumar; Nuzhat Husain; Jitendra K Kushwaha; Abhinav A Sonkar
Journal:  Breast Care (Basel)       Date:  2017-06-16       Impact factor: 2.860

3.  Prognostic role of E-cadherin and Vimentin expression in various subtypes of soft tissue leiomyosarcomas.

Authors:  Wei Tian; Guowen Wang; Jilong Yang; Yi Pan; Yulin Ma
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

4.  Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?

Authors:  Damoun Safarpour; Shabnam Pakneshan; Fattaneh A Tavassoli
Journal:  Am J Cancer Res       Date:  2014-07-16       Impact factor: 6.166

5.  Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.

Authors:  Branka Petrić Miše; Vesna Dobrić Telesmanić; Snježana Tomić; Dinka Šundov; Vesna Čapkun; Eduard Vrdoljak
Journal:  Pathol Oncol Res       Date:  2014-08-11       Impact factor: 3.201

6.  Advantages of adjuvant chemotherapy for patients with triple-negative breast cancer at Stage II: usefulness of prognostic markers E-cadherin and Ki67.

Authors:  Shinichiro Kashiwagi; Masakazu Yashiro; Tsutomu Takashima; Naoki Aomatsu; Katsumi Ikeda; Yoshinari Ogawa; Tetsuro Ishikawa; Kosei Hirakawa
Journal:  Breast Cancer Res       Date:  2011-11-30       Impact factor: 6.466

7.  Down-regulated E-cadherin expression is associated with poor five-year overall survival in bone and soft tissue sarcoma: results of a meta-analysis.

Authors:  Ning Wang; Yong-Lai He; Li-Juan Pang; Hong Zou; Chun-Xia Liu; Jin Zhao; Jian-Ming Hu; Wen-Jie Zhang; Yan Qi; Feng Li
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

Review 8.  The role of the androgen receptor in ovarian cancer carcinogenesis and its clinical implications.

Authors:  Haiyan Zhu; Xuejie Zhu; Lihong Zheng; Xiaoli Hu; LuZhe Sun; Xueqiong Zhu
Journal:  Oncotarget       Date:  2017-04-25

9.  Hormonal Homologies between Canine Mammary Cancer and Human Breast Cancer in a Series of Cases.

Authors:  Paloma Jimena de Andrés; Sara Cáceres; Juan Carlos Illera; Belén Crespo; Gema Silván; Felisbina Luisa Queiroga; Maria José Illera; Maria Dolores Pérez-Alenza; Laura Peña
Journal:  Vet Sci       Date:  2022-07-29

10.  Expression of Androgen Receptor in Estrogen Receptor-positive Breast Cancer.

Authors:  Anil Agrawal; Piotr Ziolkowski; Zygmunt Grzebieniak; Michal Jelen; Piotr Bobinski; Siddarth Agrawal
Journal:  Appl Immunohistochem Mol Morphol       Date:  2016-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.